GH signaling has been involved in promoting resistance to anticancer therapies through the induction of ATP-binding cassette (ABC) multidrug transporters in various cancers, including melanoma [11,55], pancreatic [10], bladder [14], breast [56], and liver cancer [37]. Here, GH1 is linked to melanoma.